Table 1

Study overview

StudyYearDesignPts/pts with NOS* (%)Flow diversion devices usedDedicated NOS F/UComments
Yu et al222012PM143/14 (10.2%)PEDNR
Szikora et al282013PS29/16 (55.2%)PED, SilkNROverlap with PUFS/Sahlein et al46
O’Kelly et al262013PM97/36 (37.1%)PEDNoData discrepancy in the manuscript, data from text were used
Moon et al352014RS20/19 (95%)PEDNRData recalculated
Tanweer et al372014RS41/19 (46.3%)PEDYesData discrepancy in the manuscript, data from text were used
Zanaty et al342014RS157/51 (33.8%)PEDNR
Zhou et al382014PS28/11 (39.3%)TubridgeNR
Puffer et al312014PM44/24 (54.5%)PED, Silk, SurpassNROverlap with PUFS/Sahlein et al.46. Data recalculated
Sahlein et al462015PM108/39 (36.1%)PEDYesOnly patients with initial aneurysm-induced NOS included
Zanaty et al452015RS44/12 (27.3%)PEDNR
Breu et al492016RS28/10 (53.7%)Silk, PEDNRData recalculated
Kim et al532016RM45/18 (40%)PEDNR
Brown et al542016RM45/45 (100%)PEDNROverlap with PUFS/Sahlein et al46
Miyachi et al642017RM24/18 (75%)PEDNoData recalculated
Silva et al712018RS115/21 (18.3%)PEDNR
Oishi et al732018RS100/38 (38%)PEDNR
Yan et al792019RS126/50 (39.7%)PEDNRData recalculated
Wang et al762019RS22/22 (100%)PEDNoData recalculated
Boulouis et al72021RM55/54† (98.2%)PED, Silk, p64, Derivo, SurpassNoRaw data access
Fujii et al932022RS112/29 (25.9%)PEDNRPotential overlap with Oishi et al73
Xu et al952022RS189/29 (15.3%)PEDYes
Lee et al942022RS49/28 (57.1%)NRNR
  • *NOS=neuro-ophthalmological symptoms induced by internal carotid artery aneurysm, treated with flow diversion.

  • †One patient treated with parent vessel occlusion excluded from the original publication.107

  • F/U, follow-up; NR, not reported; PED, Pipeline embolization device; PM, prospective multicenter; PS, prospective single-center; RM, retrospective multi-center; RS, retrospective single-center.